Cancer Immunology, Success Without Sequencing

Restricted access

William Blum, MD, is an associate professor of internal medicine at The Ohio State University (OSU) and James Cancer Hospital, in Columbus, Ohio, where he is Chief of the Acute Leukemia Section in the Division of Hematology. His research is focused on experimental therapeutics for acute leukemia, especially acute myeloid leukemia (AML). He serves as a cadre member of the Alliance Leukemia Core Committee and as Chair of the OSU Data and Safety Monitoring Committee. His main interest is advancing the care of older patients with AML, including development of alternatives to intensive induction chemotherapy.

The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.

  • 1.

    Couzin-Frankel J. Breakthrough of the year 2013: cancer immunotherapy. Science 2013;342:14321433.

  • 2.

    Porter DL, Levine BL, Kalos M. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;25;365:725733.

  • 3.

    Grupp SA, Kalos M, Barrett D. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:15091518.

  • 4.

    Goede V, Fischer K, Busch R. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014, in press.

  • 5.

    Hodi FS, O’Day SJ, McDermott DF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711723.

  • 6.

    Wolchok JD, Kluger H, Callahan MK. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122133.

  • 7.

    Weber JS, Kudchadkar RR, Yu B. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013;31:43114318.

    • Search Google Scholar
    • Export Citation
  • 8.

    Hamid O, Robert C, Daud A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134144.

  • 9.

    Brahmer JR, Tykodi SS, Chow LQ. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:24552465.

    • Search Google Scholar
    • Export Citation
  • 10.

    Venstrom JM, Pittari G, Gooley TA. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012;367:805816.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 112 82 1
PDF Downloads 10 8 0
EPUB Downloads 0 0 0